Centessa Pharmaceuticals plc Quarterly Operating Income (Loss) in USD from Q2 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Centessa Pharmaceuticals plc quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q3 2024.
  • Centessa Pharmaceuticals plc Operating Income (Loss) for the quarter ending September 30, 2024 was -$46.4M, a 15.4% decline year-over-year.
  • Centessa Pharmaceuticals plc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$162M, a 9.03% increase year-over-year.
  • Centessa Pharmaceuticals plc annual Operating Income (Loss) for 2023 was -$171M, a 19.3% increase from 2022.
  • Centessa Pharmaceuticals plc annual Operating Income (Loss) for 2022 was -$212M, a 43.3% increase from 2021.
  • Centessa Pharmaceuticals plc annual Operating Income (Loss) for 2021 was -$374M, a 3483% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$162M -$46.4M -$6.2M -15.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$155M -$44M +$3.04M +6.46% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$158M -$36.1M +$12.8M +26.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$171M -$35.2M +$6.43M +15.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$178M -$40.2M +$8.82M +18% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$187M -$47M +$21.4M +31.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$208M -$48.9M +$4.34M +8.16% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$212M -$41.6M +$16.7M +28.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$229M -$49M -$10.7M -28% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$218M -$68.4M -$27.1M -65.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$191M -$53.2M +$183M +77.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$374M -$58.3M -$57.5M -7345% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$317M -$38.3M -$36.2M -1711% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$280M -$41.3M -$39.2M -1839% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 -$241M -$236M Jan 30, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$783K Jan 1, 2021 Jan 29, 2021 10-K 2023-03-30
Q3 2020 -$2.12M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$2.13M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.